OncoMatch/Clinical Trials/NCT07044544
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Is NCT07044544 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including G-CSF and Decitabine for myeloid malignancy.
Treatment: G-CSF · Decitabine · Venetoclax — The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Demographics
Prior therapy
Cannot have received: autologous hematopoietic stem cell transplant
Exception: allowed if > 3 months prior to enrollment
Autologous hematopoietic stem cell transplant < 3 months prior to enrollment
Cannot have received: allogeneic stem cell transplant
Previous allogeneic stem cell transplant
Lab requirements
Kidney function
calculated creatinine clearance > 50 mL/minute (Cockcroft-Gault formula, actual body weight)
Liver function
total bilirubin < 1.5x ULN (Gilbert's Disease allowed up to <3mg/dl); ALT/AST < 2.5x ULN
Cardiac function
ejection fraction >40%
Cardiac function: Ejection fraction >40%; Calculated creatinine clearance greater than 50 mL/minute (using the Cockcroft-Gault formula and actual body weight). Pulmonary function: DLCO ≥50% (adjusted for hemoglobin) and FEV1≥50%. Liver function: total bilirubin < 1.5x the upper limit of normal and ALT/AST < 2.5x the upper normal limit. Patients who have been diagnosed with Gilbert's Disease are allowed to exceed the defined bilirubin value up to <3mg/dl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07044544 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify